参考文献/References:
[1] Folkman J. Tumor angiogenesis: therapeutic implications [J]. N Engl J Med, 1971, 285(21): 1182-1186.
[2] Marijo, Bilusic, Yu-Ning Y, et al. Anti-angiogenesis in prostate cancer:knocked down but not out[J]. Asian J Androl, 2014, 16(3): 372-377.
[3] Russo G, Mischi M, Scheepens W, et al. Angiogenesis in prostate cancer:onset,progression and imaging[J]. BJU Int, 2012, 110(11c): E794-E808.
[4] Anai S, Sakamoto N, Sakai Y, et al. Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer [J]. Urol Oncol, 2011, 29(4): 421-429.
[5] Rosenberg EE, Prudnikova TY, Zabarovsky ER, et al. Dglucuronyl C5-epimerase cell type specifically affects angiogenesis pathway in different prostate cancer cells [J]. Tumor Biology, 2014, 35(4): 3237-3245.
[6] Chen FF, Wang M, Bai J, et al. Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer [J]. PLoS One, 2014, 9(1): e86917.
[7] Marignol L, Rivera-Figueroa K, Lynch TA. Hypoxia, notch signalling, and prostate cancer [J]. Nat Rev Urol, 2013, 10 (7): 405-413.
[8] Nguyen DP, Li JY, Yadav SS, et al. Recent insights into NF-kappa B signalling pathways and the Link between inflammation and prostate cancer[J]. BJU Int, 2014, 114(2): 168-176.
[9] Varkaris A, Katsiampoura AD, Araujo JC, et al. Src signaling pathways in prostate cancer [J]. Cancer Metastasis Rev, 2014, 33 (2/3, SI): 595-606.
[10] Gu M, Roy S, Raina K, et al. Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target[J]. Cancer Res, 2009, 69(24): 9465-9472.
[11]刘秋英 ,王一飞 .血管生成及其抑制剂在前列腺癌中的研究进展[J].中国病理生理杂志, 2004, 20(12): 2347-2352.
[12] Littlepage LE, Sternlicht MD, Rougier N, et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression [J]. Cancer Res, 2010, 70(6): 2224-2234.
[13] Terraneo L, Virgili E, Caretti A, et al. In vivo hyperoxia induces hypoxia-inducible factor-1alpha overexpression in LNCaP tumors without affecting the tumor growth rate [J]. Int J Biochem Cell Biol, 2014, 51: 65-74.
[14] Feng S, Shao LJ, Yu WD, et al. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression [J]. Clin Cancer Res, 2012, 18(14): 3880-3888.
[15] Yang F, Strand DW, Rowley DR. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma[J]. Oncogene, 2008, 27(4): 450-459.
[16] Krishnan B, Torti FM, Gallagher PE. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1[J]. Prostate, 2013, 73(1): 60-70.
[17]徐锐,陈旭,王莉,等.肿瘤坏死因子 -α在前列腺癌组织中的表达及临床意义[J].华西医学,2015, 30(3): 407-410.
[18] Gyftopoulos K, Vourda K, Sakellaropoulos G, et al. The angiogenic Switch for vascular endothelial growth Factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and gleason grade [J]. Urol Int, 2011, 87(4): 464-469.
[19] Tkacz VL, Tohnya TM, Figg WD. Cyclooxygenase-2 and angiogenesis in prostate cancer [J]. Cancer Biol Ther, 2005, 4(8): 813-814.
[20] Nassar ZD, Moon H, Duong T, et al. PTRF/cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis [J]. Oncotarget, 2013, 4(10): 1844-1855.
[21] Levenson AS, Kumar A, Zhang X. MTA family of proteins in prostate cancer: biology, significance, and therapeutic opportunities[J]. Cancer Metastasis Rev, 2014, 33(4, SI): 929-942.
[22] Liu X, Peng J, Sun WC, et al. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice [J]. Tohoku J Exp Med, 2012, 228(2): 147-156.
[23] Laderach DJ, Gentilini LD, Giribaldi L, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease [J]. Cancer Res, 2013, 73(1): 86-96.
[24] Kwon SJ, Lee GT, Lee JH, et al. Mechanism of Pro-Tumorigenic effect of BMP-6: neovascularization involving Tumor-Associated macrophages and IL-1 alpha[J]. Prostate, 2014, 74(2): 121-133.
[25] Detchokul S, Newell B, Williams ED. CD151 is associated with prostate cancer cell invasion and lymphangiogenesis in vivo [J]. Oncol Rep, 2014, 31(1): 241-247.
[26] Gravina GL, Mancini A, Ranieri G, et al. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples[J]. Int J Oncol, 2013, 42(6): 2116-2122.
[27] Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: Effectors of angiogenesis and tumor progression [J]. Biochim Biophys Acta, 2009, 1796(1): 11-18.
[28] Chen PC, Cheng HC, Wang J, et al. Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment[J]. Oncotarget, 2014, 5(6): 1595-1608.
[29] Kwon SJ, Lee GT, Lee JH, et al. Mechanism of Pro-Tumorigenic effect of BMP-6: neovascularization involving Tumor-Associated macrophages and IL-1 alpha[J]. Prostate, 2014, 74(2): 121-133.
[30] Tomic TT, Gustavsson H, Wang WA, et al. Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2 [J]. Prostate, 2012, 72(7): 705-712.
[31] Oh SJ, Erb HH, Hobisch A, et al. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways [J]. Endocr Relat Cancer, 2012, 19(3): 305-319.
[32] Henry JY, Lu L, Adams M, et al. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo [J]. Prostate, 2012, 72(8): 856-867.
[33] Olsson A, Bjork A, Vallon-Christersson J, et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors[J]. Mol Cancer, 2010, 9: 107.
[34] Zhao LL, Ching LM, Kestell P, et al. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability [J]. Int J Cancer, 2005, 116(2): 322-326.
[35] Rosen LS, Hurwitz HI, Wong MK, et al. A phase I First-in-Human study of TRC105 (Anti-Endoglin antibody) in patients with advanced cancer[J]. Clin Cancer Res, 2012, 18(17): 4820-4829.
[36] Gacche RN. Compensatory angiogenesis and tumor refractoriness [J]. Oncogenesis, 2015, 4: e153.
相似文献/References:
[1]李辽源,高新,李解方,等.血清/尿PSA比值对血清PSA处于"灰区"中前列腺癌的诊断价值[J].中华腔镜泌尿外科杂志(电子版),2008,(03):52.
LI Liao-yuan,GAO Xin,LI Xie-fang,et al.The role of the ratio of serum PSA and urine PSA in diagnosing prostate carcinoma within the serum PSA "gray" zone[J].,2008,(06):52.
[2]仲飞,郝吉庆,孙国平.多西他赛联合卡培他滨治疗激素抵抗性晚期前列腺癌的近期疗效[J].中华腔镜泌尿外科杂志(电子版),2011,(04):278.
ZHONG Fei,HAO Jiqing,SUN Guo-ping.Effects of docetaxel and capecitabine for hormone-refractory prostate cancer[J].,2011,(06):278.
[3]何必鸣,陈锐,高旭,等.前列腺癌术后病理较穿刺病理Gleason 评分升高的相关因素[J].中华腔镜泌尿外科杂志(电子版),2016,10(02):77.[doi:10.3877/cma.j.issn.1674-3253.2016.02.002]
[4]周骏,梁朝朝,施浩强,等.腹腔镜前列腺癌根治术的技术改良与再认识[J].中华腔镜泌尿外科杂志(电子版),2016,10(02):80.[doi:10.3877/cma.j.issn.1674-3253.2016.02.003]
[5]罗子寰,陆敏华,黄群雄,等.DOPEY2 在TMPRSS2-ERG 基因融合
阴性前列腺癌中的表达及临床意义[J].中华腔镜泌尿外科杂志(电子版),2016,10(02):127.[doi:10.3877/cma.j.issn.1674-3253.2016.02.015]
[6]施振凯,高旭,王海峰,等.机器人辅助筋膜内前列腺癌根治术对术后尿控影响的研究[J].中华腔镜泌尿外科杂志(电子版),2016,10(01):8.[doi:10.3877/cma.j.issn.1674-3253.2016.01.003
]
Shi Zhenkai,Gao Xu,Wang Haifeng,et al.Urinary function of intrafascial robot-assisted laparoscopic radical prostatectomy[J].,2016,10(06):8.[doi:10.3877/cma.j.issn.1674-3253.2016.01.003
]
[7]林立国,吴国忠,孙忠凯,等.经尿道前列腺电切术诊治高度疑似晚期前列腺癌并膀胱出口梗阻[J].中华腔镜泌尿外科杂志(电子版),2016,10(04):230.[doi:10.3877/cma.j.issn.1674-3253.2016.04.004
]
Lin Liguo,Wu Guozhong,Sun Zhongkai,et al.Transurethral resection of prostate to diagnose and treat the patients with highly suspected advanced prostate cancer and lower urinary tract symptoms[J].,2016,10(06):230.[doi:10.3877/cma.j.issn.1674-3253.2016.04.004
]
[8]杨波 邓晓俊 温晓飞 陈卫华 刘辉 刘峰 王伟峰 郝继东 万建省 廖国强.经直肠弹性超声穿刺活检联合墨水标记法病理诊断前列腺癌的研究[J].中华腔镜泌尿外科杂志(电子版),2016,10(05):296.[doi:10.3877/cma.j.issn.1674-3253.2016.05.002
]
Yang Bo,DengXiaojun,WenXiaofei,et al.The clinical research of biopsy of prostate cancer by transrectal ultrasound elastography combined ink marking[J].,2016,10(06):296.[doi:10.3877/cma.j.issn.1674-3253.2016.05.002
]
[9]杨逢生,李宝兴,刘文泓,等.经腹与经腹膜外途径腹腔镜前列腺癌根治术疗效比较的Meta分析[J].中华腔镜泌尿外科杂志(电子版),2016,10(05):301.[doi:10.3877/cma.j.issn.1674-3253.2016.05.003
]
Yang Fengsheng,Li Baoxing,Liu Wenhong,et al.Comparison of transperitoneal and extraperitoneal laparoscopic radical prostatectomy: a Meta analysis[J].,2016,10(06):301.[doi:10.3877/cma.j.issn.1674-3253.2016.05.003
]
[10]曹达龙 叶定伟 戴波 张海梁 沈益君 朱一平 施国海 马春光 肖文军 秦晓健 林国文 朱耀.腹腔镜前列腺癌根治术时对腺体突向膀胱的优化处理：附视频[J].中华腔镜泌尿外科杂志(电子版),2015,(05):317.[doi:10.3877/cma.j.issn.1674-3253.2015.05.002
]
Cao Dalong,Ye Dingwei,et al.The optimized treatment of prostate gland protruding to bladder in laparoscopic radical prostatectomy[J].,2015,(06):317.[doi:10.3877/cma.j.issn.1674-3253.2015.05.002
]